The company was able to offset deeper COVID-related declines on the strength of its advanced DBM portfolio and plans to pursue several alpha launches of new products in 2020.
Geographic factors and a highly elective portfolio exposed the company to a severe downturn due to COVID-19, with 1Q20 revenue down 20% and April revenues down 95%.
This is the first carbon composite spinal rod cleared for market as an adjunct in the treatment of spinal indications, other than oncological.
Hive lattice devices with NanoHive Surface Technology is designed to offer ideal elastic modulus, diagnostic imaging and osteogenic properties.
While the company's orthopedic revenues declined in the high single-digits in 1Q20, Zimmer Biomet's balance sheet and cost containment measures will allow it to aggressively pursue key R&D initiatives.
The company's orthopedic business declined in mid-single digits for 1Q20, with a precipitous -80% decline in April. However, Integra expects the market to right itself by year-end.
Medacta gained FDA clearance for its M-Vizion Femoral Revision System and its Long Humeral Diaphysis for shoulder joint replacement.
The company's sales declined in the mid-single digits in 1Q20, but included a few bright spots like continuing adoption of the M6-C artificial disc.
The company's late-2019 growth momentum continued for most of 1Q20, resulting in nearly 22.6% growth. ATEC is confident the spine market will be one of the first to rebound from COVID-19.
The company was on pace to deliver double-digit growth in 1Q20 before COVID-related surgical delays, and procedures were down roughly 90% in April.